Beigene Ltd
HKEX:6160

Watchlist Manager
Beigene Ltd Logo
Beigene Ltd
HKEX:6160
Watchlist
Price: 182 HKD 0.39%
Market Cap: 248B HKD

Relative Value

The Relative Value of one Beigene Ltd stock under the Base Case scenario is 180.81 HKD. Compared to the current market price of 182 HKD, Beigene Ltd is Overvalued by 1%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
180.81 HKD
Overvaluation 1%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
69
vs Industry
47
Median 3Y
7.5
Median 5Y
7.8
Industry
7.9
Forward
6.2
vs History
vs Industry
Median 3Y
-20.4
Median 5Y
-20.3
Industry
23.7
Forward
107.5
vs History
14
vs Industry
Median 3Y
-17.4
Median 5Y
-18.1
Industry
22
vs History
9
vs Industry
Median 3Y
-13.9
Median 5Y
-15.4
Industry
23.8
vs History
17
vs Industry
11
Median 3Y
5.9
Median 5Y
5.3
Industry
3.3
vs History
65
vs Industry
40
Median 3Y
7
Median 5Y
7.4
Industry
8.3
Forward
5.9
vs History
68
vs Industry
41
Median 3Y
8.2
Median 5Y
8.6
Industry
10.1
vs History
4
vs Industry
23
Median 3Y
-13.3
Median 5Y
-13.6
Industry
6.4
Forward
56.3
vs History
4
vs Industry
21
Median 3Y
-13.3
Median 5Y
-13.6
Industry
7
Forward
82.3
vs History
14
vs Industry
23
Median 3Y
-15.2
Median 5Y
-16.1
Industry
8.3
vs History
9
vs Industry
22
Median 3Y
-10.9
Median 5Y
-11.5
Industry
6.5
vs History
23
vs Industry
19
Median 3Y
8.6
Median 5Y
8.5
Industry
5.7

Multiples Across Competitors

Competitors Multiples
Beigene Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Beigene Ltd
HKEX:6160
259.9B HKD 6.6 -1 537.7 218 218
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 770 229.5 -160 504.9 -194 904.1 -192 680.1
US
Abbvie Inc
NYSE:ABBV
395.3B USD 6.6 168.4 16.3 23.2
US
Amgen Inc
NASDAQ:AMGN
175.8B USD 4.9 25.1 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
147.5B USD 5.1 18.2 12.2 12.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.6B USD 9.9 31.4 23.1 24.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 086.1 -532.3 -579.6 -564.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.6B USD 5.5 17.2 16.3 18.5
AU
CSL Ltd
ASX:CSL
84.7B AUD 3.6 18.7 12.6 15.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
51.6B USD 16.1 1 183.4 155.3 188.4
NL
argenx SE
XBRU:ARGX
44.3B EUR 14.4 34 58.6 60.2
P/S Multiple
Revenue Growth P/S to Growth
CN
Beigene Ltd
HKEX:6160
Average P/S: 3 070 217.1
6.6
25%
0.3
FR
Pharnext SCA
OTC:PNEXF
33 770 229.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.1
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
2 086.1
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
6%
0.9
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.1
46%
0.3
NL
argenx SE
XBRU:ARGX
14.4
49%
0.3
P/E Multiple
Earnings Growth PEG
CN
Beigene Ltd
HKEX:6160
Average P/E: 187
Negative Multiple: -1 537.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 504.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.4
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.1
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.2
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.4
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
9%
1.9
AU
CSL Ltd
ASX:CSL
18.7
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 183.4
N/A N/A
NL
argenx SE
XBRU:ARGX
34
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Beigene Ltd
HKEX:6160
Average EV/EBITDA: 59
218
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 904.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.2
7%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.3
11%
1.5
AU
CSL Ltd
ASX:CSL
12.6
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
155.3
N/A N/A
NL
argenx SE
XBRU:ARGX
58.6
839%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Beigene Ltd
HKEX:6160
Average EV/EBIT: 64.3
218
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 680.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.2
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.1
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -564.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.5
13%
1.4
AU
CSL Ltd
ASX:CSL
15.8
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
188.4
N/A N/A
NL
argenx SE
XBRU:ARGX
60.2
N/A N/A